UBS initiated coverage of Biohaven with a Buy rating and $59 price target. Biohaven is a clinical stage biotech with a broad set of pipeline opportunities across multiple therapy areas, the analyst tells investors in a research note. The firm is bullish on the pipeline and believes Phase 1 BHV-1300 data in Q1 and the Phase 3 Spinal muscular atrophy readout in the second half of 2024 are positive catalysts with favorable risk/rewards.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BHVN: